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Abstract
Background: Cross-sectional studies show that transgender people are more likely 
than cisgender people to experience depression and anxiety before gender-affirm-
ing hormone treatment (GAHT). However, the effect of GAHT on mental health in 
transgender people, and the role of other factors that may have a predictive effect, 
is poorly explored.
Objectives: Using a longitudinal methodology, this study investigated the effect of 
18-month GAHT on depression and anxiety symptomatology and the predictors on 
mental health outcomes in a large population of transgender people.
Materials and methods: Participants (n = 178) completed a socio-demographic ques-
tionnaire, the Hospital Anxiety and Depression Scale (HADS), the Multidimensional 
Scale of Perceived Social Support (MSPSS) and the Autism Spectrum Quotient—Short 
Version (AQ-Short) at pre-assessment (T0) and at 18 months after initiation of GAHT 
(T1).
Results: From T0 to T1, symptomatology was significantly decreased for depression 
(P < .001) and non-significantly reduced for anxiety (P = .37). Scores on the MSPSS 
predicted reduction in depression, while scores on the AQ-Short predicted reduction 
in anxiety.
Discussion: GAHT reduces symptoms of depression which are predicted by having 
higher levels of social support. Although anxiety symptoms also reduce, the changes 
are not significant and high levels of anxiety still remain post-GAHT.
Conclusions: These results highlight the important mental health benefits of GAHT. 
Support services (professional, third sector or peer support) aiming at increasing so-
cial support for transgender individuals should be made available.
K E Y W O R D S
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1  | INTRODUC TION
Treatment-seeking transgender people who are not on hormone 
treatment have reported high levels of mental health problems, 
particularly anxiety, depression and self-harm, which are likely 
caused by a number of internal and external stressors.1-12 Studies 
examining mental health in transgender people have primarily fo-
cused on individuals attending transgender health services and 
hence those who are likely to experience a higher level of distress 
about their assigned sex at birth. These studies have primarily 
looked cross-sectionally at levels of anxiety,7,13,14 depression7,15-17 
and self-harm.18-20
With regard to anxiety, several studies have demonstrated high 
levels in transgender people before gender-affirming hormone 
treatment (GAHT).21,22 For example, Bouman et al 13 found that 
levels of anxiety in transgender people were three times higher 
than those in a matched sample from the general population. This 
study also found that transgender males were more anxious than 
transgender females. Interestingly, the high scores on autistic 
traits found among this population have been suggested to be a 
product of the high levels of anxiety and low self-esteem often 
experienced by this group15 and not autism per se.23 However, a 
recent study has demonstrated stability in autistic traits following 
GAHT.24
Similar to anxiety, high levels of depression have also been re-
ported in transgender individuals, prior to GAHT.16,18,22 Witcomb 
et al16 reported that transgender people prior to receiving GAHT 
had a fourfold increased risk of a probable depressive disorder 
compared to a matched control sample from the general popu-
lation. Why this is the case is unclear, but social factors such as 
lack of general social support,9,25-27 parental support28 and peer 
support have been found to be associated with depressive symp-
toms among transgender people.29,30 Experiences of transphobic 
discrimination are associated with increased odds of suffering 
from depression31 independent of other types of discrimination, 
for example racism. This suggests that transgender people who 
are ethnic minorities are at even greater risk, because of the inter-
sectional experience of discriminatory events. In addition, while 
unemployment increases the risk of depression in the general pop-
ulation32 and transgender people have been found to have a higher 
unemployment rate than cisgender people33—being in employ-
ment is associated with higher levels of experienced transphobia 
and fear of disclosing mental health problems in the transgender 
population.34,35
Another factor that has been associated with mental health 
problems in treatment-seeking transgender people is age. Younger 
transgender people report high levels of bullying36 and very high 
levels of self-harm,19,37 which have been associated with increased 
anxiety as well as effects on self-esteem, family relationships and 
social life, which all negatively influence mental well-being.
While these studies have provided valuable insight, the use of 
cross-sectional methodologies to examine the impact of the above 
factors, particularly the role of GAHT in mental health, is limited. 
Therefore, it is critical to explore this on a within-subject basis using 
a longitudinal design. This is the most effective approach to show 
the effects of GAHT on mental health as it provides the opportunity 
to examine individuals prior to and during GAHT.
A small number of longitudinal studies that focus on the effect 
of GAHT on mental health do exist. Colizzi et al38 reported sig-
nificant reductions in mental health symptoms after the initiation 
of GAHT with anxiety reducing from 50% to 17% and depression 
from 24% to 11%. Heylens et al39 also showed significant reduc-
tions in symptoms of anxiety and depression after the initiation 
of GAHT to the point where they resemble those of the general 
population. These studies are, however, not without limitations. 
Heylens et al’s39 study has a small sample size (n = 57), while 
Colizzi et al’s38 study is limited by the lack of evaluation of factors 
that may have impacted on the mental health of their participants, 
such as social support. Both studies describe the need to repli-
cate their findings. In contrast, Bränström and Pachankis40 using 
the Swedish population register showed no significant association 
between the likelihood of accessing mental health treatment and 
time since initiation of GAHT. The limitation of their study includes 
primarily that accessing mental health services does not neces-
sarily reflect actual mental health and there is little additional in-
formation about the type of mental health treatment received by 
their participants. These limitations mean that this study cannot 
provide reliable evidence regarding the role of GAHT on the men-
tal health symptoms of transgender people, and this information 
is vital in order to provide an evidence base of GAHT improving 
overall quality of life of transgender people.
While the available longitudinal studies have provided valuable 
evidence of the effect of GAHT on transgender people's mental 
health, there is a requirement to replicate these studies addressing 
their limitations. With this in mind, the primary aim of this study is 
to examine the effect of GAHT on anxiety and depression symp-
toms. The study will focus on those who have been on treatment 
for over 18 months as this allows for enough time for GAHT to pro-
duce physical, bodily changes but before surgical procedures have 
taken place, which could bias the results. As some physical changes 
can be quicker in assigned females at birth than in assigned males at 
birth (eg voice change with testosterone),2 which can affect men-
tal health outcome following GAHT, the results of GAHT in anxi-
ety and depression for both groups will be presented separately. 
It is hypothesized that an improvement in mental health will take 
place in those assigned male and female at birth following GAHT 
treatment. Unfortunately, because of the long waiting list for gen-
der-affirming surgical treatment in the United Kingdom (UK), it is 
unlikely that people will have undergone these interventions before 
this time. The secondary aim of this study is to examine pre-GAHT 
factors which may be predicting changes in anxiety and depression 
following GAHT. The predictors selected for this study are based on 
the literature and include ethnicity, age, assigned sex at birth, civil 
status, employment, social support, and autistic traits. This study 
hypothesized that symptoms of depression and anxiety would be 
significantly decreased after 18 months of GAHT.
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2  | MATERIAL S AND METHODS
2.1 | Participants
Participants were invited to take part through a national transgender 
health service in Nottingham, UK. This service is part of the National 
Health Service (NHS) and offers assessment for suitability of GAHT 
as well as chest and genital reconstructive surgery. The service also 
offers GAHT and speech and language therapy. The service accepts 
referrals from people aged 17 and over who are seeking, or consider-
ing, medical transition.
2.2 | Procedures
The sample consisted of individuals who attended an assessment at 
the transgender health service from November 2014 to March 2018, 
who agreed participation and who were not on GAHT prior to the as-
sessment. Prior to the clinical assessment, every patient was invited 
to participate in the study. If agreed, they were invited to complete 
a baseline questionnaire pack (T0). The pack included a socio-demo-
graphics questionnaire (age, sex assigned at birth, gender identity, eth-
nicity, employment status, relationship status and whether participants 
were taking cross-sex hormones and/or blockers pre-assessment—as a 
significant proportion of young people are referred from the only ex-
isting child and adolescent transgender health services in the United 
Kingdom). Validated questionnaires regarding anxiety and depression 
(HADS), social support (MSPSS) and autistic traits (AQ-Short) were also 
included in the information pack. Data were only included if partici-
pants returned a signed consent form with the study questionnaires.
Participants who consented and returned T0 questionnaires 
were invited to complete a T1 questionnaire 18 months after com-
mencing GAHT. The T1 questionnaire pack consisted of a HADS 
questionnaire. This allowed a comparison of changes in depression 
and anxiety symptoms before and after GAHT. Data were collected 
in October 2019. Except for the data analysis, the study was primar-
ily unfunded and set up in a busy clinic.
2.3 | Tools
2.3.1 | The Hospital Anxiety and Depression Scale 
(HADS)
The HADS is a 14-item self-report screening scale originally devel-
oped to indicate the possible presence of anxiety and depression 
states in medical non-psychiatric outpatient clinics.41 The HADS con-
sists of two subscales, HADS—Depression (HADS-D) and HADS—
Anxiety (HADS-A). Each subscale has seven items that are rated on 
a 4-point Likert scale that ranges from 0 to 4 with some items being 
reverse-scored. A maximum total of 21 can be obtained on each 
subscale. A score of 0-7 on both scales implies a non-clinical range, 
while a score of 8-10 suggests the possible presence of a depressive 
or anxiety disorder. A score of 11 or higher suggests the probable 
presence of a depressive or anxiety disorder. Caseness of depression 
and anxiety has been suggested for scores above 8.42 The HADS has 
previously been used with transgender individuals.13,43 For depres-
sion (HADS-D), this gave a specificity of 0.7 and a sensitivity of 0.9. 
For anxiety (HADS-A), this gave a specificity of 0.78 and a sensitivity 
of 0.9. In this study; Cronbach's alpha for depression was 0.76 and 
for anxiety 0.68.
2.3.2 | The multidimensional scale of perceived 
social support (MSPSS)
The MSPSS is a 12-item self-report scale to record levels of social 
support from family, friends and significant others.44 The measure 
consists of three subscales to measure the three different types of 
support. Items are rated on a Likert scale that ranges from 1 (‘very 
strongly agree’) to 7 (‘very strongly disagree’). To calculate subscale 
scores, items from each subscale are added together and divided by 
4. A total score is calculated by adding together all 12 items and di-
viding by 12. The mean and total scores range from 1 to 7 with a 
higher score indicating a higher level of perceived social support. A 
mean total scale score ranging from 1 to 2.9 can be considered low 
support; a score of 3 to 5 can be considered moderate support; and 
a score from 5.1 to 7 can be considered high support. The MSPSS has 
previously been used with transgender individuals.26,45 In this study, 
Cronbach's alpha was 0.89.
2.3.3 | Autism spectrum quotient—short version 
(AQ-Short)
The AQ-Short is a 28-item self-report questionnaire designed to 
measure autistic traits to give an indication of where the person 
lies on the continuum of the spectrum, ranging from healthy to 
autistic.46,47 It is a shortened version of the validated AQ-50.48 It 
consists of two higher order factors related to autistic traits, includ-
ing numbers and patterns (which assess the extent to which peo-
ple are fascinated by numbers, dates, patterns and categories) and 
social behaviours. The AQ-Short is a 4-point Likert scale ranging 
from ‘definitely agree’ to ‘definitely disagree’, with some items being 
reverse-scored. Total scores range between 28 and 112. The AQ-
Short has previously been used with transgender populations.23,24,49 
Higher scores represent higher levels of autistic traits. Although not 
intended to be a diagnostic tool, a cut-off of ≥ 70 was found to have a 
sensitivity of 0.94 and specificity of 0.91 to discriminate between an 
autism sample and a community sample. Cronbach's alpha was 0.86.
2.3.4 | Data analysis
Data analyses were performed using the Statistical Software Package 
Stata 16.50 Stata 16 was used to conduct power analysis. Only those 
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participants not on GAHT at assessment (T0) were included in the re-
gression analysis. All missingness was imputed using analytical model 
with 20 imputed data sets generated for each model. Paired sample 
t tests were used to determine whether there had been a significant 
change in the HADS-D and HADS-A subscales from T0 to T1. Multiple 
regression was conducted to explore ethnicity, employment status, re-
lationship status, age, assigned sex, MSPSS and AQ. The hypothesis 
regarding whether the specific factors were predictive of changes in 
anxiety and depression was tested via a moderator analysis, entering 
only the subscales found to be significant in the linear regressions and 
a product of their combined centred scores. This was tested via a multi-
ple regression. Bonferroni corrections were used to correct multiplicity 
issue if needed. Although data are not normally distributed, Allison51) 
states that normality is the least important assumption of regression 
and as data met the assumptions for linearity, homoscedasticity and 
absence of multicollinearity or extreme outliers, a multiple regression 
analysis was conducted. The socio-demographic categories were split 
into two distinct groups for each category as seen in Table 1. Assigned 
sex at birth instead of gender identity was used in the socio-demo-
graphics in view of the many different gendered identities described, 
as an analysis based on gender identities would have made the analyses 
too complex to interpret; this followed previous study approaches.23,24 
The MSPSS and AQ-28 Short at T0 were significant factors predicting 
change in HADS-D and HADS-A at T1. To check the robustness of re-
gression estimates sensitive to missingness, all regression models were 
re-run on observed data only and the results were examined against 
the results from imputed data set.
Ethical approval for the study was received from the NHS Ethics 
Committee (14/EM/0092) and the Research and Development 
Department at Nottinghamshire Healthcare NHS Foundation Trust 
in line with Health Research Authority guidance,52 which included 
approval for individuals aged 17 and over to sign giving their consent 
without the need for additional parental consent.
3  | RESULTS
3.1 | Socio-demographic characteristics of the 
participants
A total of 1,271 participants were assessed between November 
2014 and March 2018, completed T0 questionnaires and agreed 
participation in the study. Seventy-one per cent (N = 906) could be 
included in the analysis as they had not received hormones prior to 
assessment. Of these, 178 (20%) went on to complete a T1 question-
naire after 18 months of GAHT, indicating a response rate of 20%. 
Responders did not differ from non-responders in terms of either 
demographic characteristics or baseline AQ-Short scores, but they 
were significantly less anxious at baseline than non-responders (me-
dian 9 vs 8, P = .001; z = 3.225) (see Table 1).
The age range from the 178 participants that completed T0 and 
T1 questionnaires ranged from 17 to 79 years with a median age of 
23 years. More than half of the participants (n = 95; 53.3%) were 
assigned male sex at birth, and 83 (46.7%) were assigned female sex 
at birth. The large majority of participants classified themselves as 
white (n = 167; 94%), were single (n = 120; 69%) and were in em-
ployment (n = 75; 41%) or students (n = 58; 32%). Participants who 
were assigned male sex at birth were more likely to be in employ-
ment compared to participants assigned female sex at birth (47% vs 
33%), while more participants assigned female sex at birth were sin-
gle at the time of assessment (78% vs 57%) and a higher percentage 
of participants assigned male sex at birth were divorced/separated 
(18% vs 2%) (see Table 1).
TA B L E  1   Socio-demographic characteristics (n,%) and mean 
(SD) scores on HADS, MSPSS and AQ-Short score of all responders 
assigned male and female at birth
Responders
Assigned 
male at 
birth (2)
Assigned 
female at 
birth (1)
n = 178 n = 95 n = 83
n% n% n%
Age, median (range) 
years
23 (1774) 28 (1779) 21 (1764)
Ethnic origin n (%)
White 167 94 92 97 75 91
Other 11 6 3 3 8 9
Not known - - - - - -
Employment status n (%)
Employed (1) 75 41 45 47 28 33
Student (2) 58 32 20 21 37 44
Housewife/
househusband (4)
- - - - - -
Voluntary work (3) 7 4 5 5 2 2
Retired (6) 5 3 6 6 - -
Disabled (5) 7 5 5 5 3 3
Unemployed (0) 26 14 14 14 12 14
Not known (9) 1 1 1 1
Civil status n (%)
Single (1) 120 69 55 57 65 78
Married (2) 15 7 12 12 1 1
Civil partner ( 3) 5 3 - - 5 6
In a relationship (7) 4 3 1 1 4 4
Divorced/separated 
(4)
20 11 18 18 2 2
Widowed (5) 2 2 2 2 1 1
Other (6) - - - - - -
Not known 
(9 + Blanks)
12 7 7 7 5 6
HADSD 7.24 (4.03) 7.03 (4.11) 7.48 (3.94)
HADSA 8.07 (4.34) 7.54 (4.31) 8.69 (4.32)
MSPSS 4.85 (1.29) 4.64 (1.35) 5.1 (1.16)
AQ 64.77 (11.86) 62.83 
(11.94)
66.97 
(11.44)
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3.2 | Anxiety and depression scores
The mean score for the total group for anxiety was 8.07 (SD: 4.34). 
It was higher in those assigned female (8.69 (SD: 4.32)) versus those 
assigned male at birth (7.54 (SD: 4.31). The mean score for depres-
sion was 7.24 (SD: 4.03), also higher in assigned females (7.48 (SD: 
3.94)) than assigned males at birth (7.03 (SD: 4.11)).
At T0 (before hormone treatment), 51.13% of participants scored 
8 or over on the HADS-A subscale, and in the case of the HADS-D 
subscale, 47.75% of participants scored above 8 placing these partic-
ipants within the categories of possible to probable presence of an 
anxiety or depression disorder. At T1, 47.19% of participants scored 
8 or above in the HADS-A subscale showing a reduction of 3.94%, 
and in the HADS-D subscale, 25.84% of people scored 8 or above 
showing a reduction of 21.91%.
3.3 | Change in anxiety and depression scores 
between T0 and T1
There was a statistically significant reduction in mean scores of 
HADS-D from T0 to T1 (mean change difference, −2.05; 95% CI, 
−2.72 to −1.38; P = .00). This indicated a reduction in depression 
following 18 months of GAHT. There was also a reduction in the 
HADS-A score from T0 to T1, but this was not statistically significant 
(mean change difference, −0.31; 95% CI, −0.97 to 0.36, P = .37). The 
same findings (a significant reduction in HADS-D and a non-signifi-
cant reduction in HADS-A) were found when comparing T0 and T1 
according to sex assigned at birth (see Table 2).
3.4 | Predictors of anxiety and depression change 
after hormone treatment
Two multiple regressions with seven predictor variables were con-
ducted to explore the predictors of change, from T0 to T1, in scores 
on HADS-D and HADS-A. The predictors for each were ethnicity, 
employment status, relationship status, assigned sex at birth, and 
age. MSPSS and AQ-Short at T0 were used as independent variables 
for both regressions.
The results for the first regression showed that overall, the 
model was significant (F(7,152)=2.09, P = .04) and explained 8.8% 
(R2 = 0.088) of the total variance in depression scores. The model 
also showed that mean MSPSS scores at T0 were the only significant 
predictor of HADS-D change between T0 and T1 (β = 0.81, P = .006). 
The second regression showed that overall, the model was significant 
(F(7,152)=2.09, P = .048) and explained 8.8% (R2 = 0.088) of the total 
variance in anxiety scores. The model also showed mean AQ-Short 
scores at T0 was a significant predictor of HADS-A change between 
T0 and T1 (β = −0.069, P = .034). The findings suggest that only 
levels of social support (MSPSS scores) and autistic spectrum traits 
(AQ scores) were able to predict changes in anxiety and depression 
following 18 months of GAHT. Having higher levels of social support T
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(higher scores of MSPSS) predicted a reduction in depression scores 
following 18 months of GAHT (P = .006) and having lower levels of 
autistic spectrums traits (lower AQ scores) predicted a reduction of 
anxiety symptoms following 18 months of GAHT (P = .03), although 
this reduction was statistically non-significant (see Table 3).
4  | DISCUSSION
This prospective longitudinal study aimed to explore whether 
18 months of GAHT reduces symptoms of anxiety and depression 
in transgender people, while addressing the limitations of previ-
ous studies, by recruiting a large sample of participants within the 
same setting. The study found a significant reduction in symptoms 
of depression in transgender individuals after 18 months of start-
ing GAHT, with a more than one-fifth decrease in the number of 
participants who scores reflected a possible or probable depressive 
disorder. A statistical reduction of anxiety was not found. While re-
ductions in depression, and to a lesser extent anxiety, were seen, a 
significant proportion of participants still present, post-treatment, 
with a possible or probable depressive disorder (25.84%) or anxi-
ety disorder (47.19%). Data from previous studies in the field were 
used to compare these findings with the general population.13,16 
Acknowledging that direct comparison cannot be made, our study 
showed that the levels of possible and probable anxiety and depres-
sive disorder after GAHT were still significantly higher than those 
reported in the general population (4.5% for possible or probable 
depressive disorder16 and 34.5% for possible or probable anxiety 
disorder).13 Whether these elevated levels will reduce further (when 
a longer use of GAHT +/− surgical interventions) needs to be ex-
plored. Thus, future longitudinal studies would benefit from fol-
lowing people for longer in order to track the longer-term impact of 
interventions.
These findings do confirm, once again, the high levels of possi-
ble anxiety and depressive disorders before GAHT and the benefit 
that this treatment brings. It highlights the need to facilitate the 
expedited use of GAHT to aid the reduction of poor mental health 
symptoms in the transgender population, when possible and ap-
propriate. This conclusion supports the literature which has called 
for longitudinal studies such as this to replicate the findings from 
cross-sectional studies.15,16,22,25,38,45 The large reduction in de-
pression, comparing to anxiety, may indicate that GAHT targets 
the dysphoria that many people attending transgender health ser-
vices present with, which is manifested as depression (rather than 
anxiety). The fact that many transgender people still feel anxious 
after GAHT may be because of the victimisation, discrimination and 
social rejection experienced by the transgender population.3,5,10,53 
Unfortunately for some, these experiences do not necessarily stop 
after initiation of GAHT, and in some cases, they may increase. 
Clinical and community services should take these findings into 
consideration and increase the support offered even after gen-
der-affirming medical treatment is over.
Importantly, this study also highlights how levels of pre-treat-
ment social support are predictive of reduced risk post-treatment, as 
higher levels of social support prior to receiving GAHT significantly 
predict a greater reduction in depression symptoms after 18 months 
of receiving GAHT. This indicates the importance of increasing social 
support in transgender people.
The study also found that those with higher levels of autistic 
spectrum condition (ASC) traits prior to the receipt of GAHT had 
lower reductions in anxiety symptoms. This could indicate that those 
with greater ASC traits have higher anxiety symptoms even after 
post-treatment or that higher ASC traits are simply reflective of dif-
ficulties in social interactions, as a result of being anxious, grounded 
in an individual's gender identity status. These findings corroborate 
cross-sectional studies which have shown that interpersonal inter-
actions can have an impact upon transgender people's psychological 
well-being.9,15,23,25,27 However, these results need to be interpreted 
with caution because of the lack of validity of the AQ-Short in this 
population.
TA B L E  3   Predictive role of ethnicity, employment status, relationship status, assigned gender at birth, age, MSPSS and AQ-Short for 
change in HADS-D and HADS-A from T0 to T1
HADS − D HADS − A
Coef. 95% CI P Coef. 95% CI P
Ethnicity (grouped as White and all other at T0) −0.37 −3.19 to 2.45 .794 −0.67 −3.62 to 2.28 .652
Employment (grouped as unemployed and disabled 
and all other at T0)
−0.97 −2.75 to 0.81 .284 −0.51 −2.37 to 1.35 .591
Relationship (grouped as single, widowed, 
divorced/separated and other at T0 and all other)
0.31 −1.82 to 2.43 .776 −0.61 −2.83 to 1.62 .590
Assigned sex at T0 0.36 −1.21 to 1.93 .651 −0.17 −1.81 to 1.47 .841
Age at T0 0.06 −0.50 to 0.61 .843 −0.03 −0.08 to 0.03 .409
Mean MSPSS at T0 0.81 0.24 to 1.39 .006 0.56 −0.04 - 1.16 .065
Mean AQ − Short at T0 −0.04 −0.096 to 0.025 .250 −0.07 −0.13 to 0.05 .034
Constant −1.93 −4.76 to 0.90 .179 0.41 −2.34 to 3.16 .787
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With social support (from families, friends or significant oth-
ers) being highlighted as a factor in depression, it is important to 
consider approaches to aiding in the building of social support net-
works for transgender people accessing transgender services. Such 
support does not necessarily need to be based in clinical settings, 
as online and offline peer support and the work of tertiary services 
are available, less stigmatizing and have demonstrated a positive 
impact.29,30,54 Resources such as peer support workers (PSWs) and 
online peer-to-peer support may be a valuable tool to provide social 
support for transgender individuals awaiting and receiving GAHT. 
Additional support is recommended in particular to those with 
higher levels of ASC traits because of the lower reductions in anxi-
ety symptoms found in this population. However, PSWs need to be 
appropriately trained in order to reduce any potential risks related to 
managing their own stress as well as power imbalances within peer 
and professional relationship.30
Regarding expedited access to GAHT, there are practical issues 
that must be considered.55-57 Many countries either lack clinical 
services specializing in transgender health care or have significant 
waiting lists to access these services.13,58-60 These practical issues 
surrounding accessing treatment can lead to self-prescribing of 
GAHT, with 23% of individuals referred to transgender health clin-
ics using GAHT prior to their first appointment, 70% of which was 
sourced online.61 Self-prescribing without medical oversight pres-
ents its own risks, most notably a lack of specialized knowledge re-
quired to minimize health risks.61
The issues surrounding access to GAHT may be compounded by 
how services are configured. The role of many mental health work-
ers in transgender health services in the UK is seen as gatekeepers, 
focused on the assessment of transgender people with limited atten-
tion given to psychological support. A shift in roles from gatekeeping 
to tangible mental health support would allow for a partial address-
ing of the power imbalance between transgender people and mental 
health professionals. This would potentially allow for transgender 
people to feel more able to discuss issues without fear of rejection 
for treatment. This in turn would provide mental health profession-
als with the ability to focus more on supporting the mental health of 
those transgender people who need it. From the evidence provided 
by this study, it appears that this would be most important for those 
with low levels of social support and those with autistic traits.
The strengths of this paper are the large sample and the natural-
istic prospective longitudinal design within one transgender health 
service, which allows for within-subject comparisons and so pro-
vides a highly valid insight into the impact of GAHT on depression 
and anxiety of treatment-seeking transgender people. It is important 
to add that this is a national NHS service, which offers gender-af-
firming medical interventions and assessment free at the point of 
access to people from different geographical regions within the UK. 
This study is one of the few in the literature currently addressing the 
role of GAHT on mental health with such a methodology.
There are, however, limitations to the study. We must acknowl-
edge that participants may downplay their symptoms of depres-
sion and anxiety pre-assessment, for fear of not being treated. 
Consequently, participants may have attenuated their mental health 
symptoms because of concern of not being accepted for GAMT. This 
could indicate that the changes between T0 and T1 may be more sig-
nificant than recorded. As the method of recruitment was through 
a transgender health clinic as part of the NHS, the findings are only 
generalizable to treatment-seeking transgender individuals. A limita-
tion may also be the response rate. Although this is low, it is in line 
with other clinical studies and it may be a reflection of the unfunded 
nature of the study. Another limitation is that the sample consisted 
of predominantly white participants, which may explain why ethnic-
ity was not a predictive factor and the lack of control group where 
the intervention (GAHT) is not being offered (eg waiting list), but this 
will have its limitations too. A full randomized control study within 
this area will not be ethically possible. Studies using data from a clin-
ical setting must also be aware of the context in which their data are 
being gathered.
In conclusion, this study shows that the mental health of trans-
gender individuals improves following GAHT, particularly for those 
who reported high levels of social support prior to receiving GAHT. 
These results highlight the important mental health benefits of 
GAHT and emphasises the need for interventions focused on devel-
oping social support for transgender individuals.
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